Table 4.

Survival analysis in different tumor types

Variables	OS (model 0)		OS (model 3)
	Crude HR(95%CI)	Crude P	Adjusted HR(95%CI)	Adjusted P
Lung cancer
CTI < 4.71	ref		ref
CTI ≥ 4.71	1.51 (1.16–1.97)	0.002	1.22 (0.93–1.61)	0.151
Esophagus cancer
CTI < 4.71	ref		ref
CTI ≥ 4.71	2.64 (1.61–4.34)	< 0.001	2.11 (1.05–4.21)	0.035
Gastric cancer
CTI < 4.71	ref		ref
CTI ≥ 4.71	1.70 (1.21–2.4)	0.002	1.28 (0.86–1.9)	0.221
Colorectal cancer
CTI < 4.71	ref		ref
CTI ≥ 4.71	3.24 (2.15–4.89)	< 0.001	2.29 (1.42–3.71)	0.001
Female tumor
CTI < 4.71	ref		ref
CTI ≥ 4.71	3.02 (1.32–6.92)	0.009	1.51 (0.49–4.59)	0.472
Other cancer
CTI < 4.71	ref		ref
CTI ≥ 4.71	2.47 (1.63–3.73)	< 0.001	1.82 (1.15–2.89)	0.011

Model 0: Unadjusted

Model 3: Adjusted for age, sex, BMI, tumor stage, KPS, surgery, chemotherapy, radiotherapy, smoking status, alcohol consumption, KPS, EORTC QLQ-C30, ECOG PS, PGSGA, diabetes, hypertension, coronary heart disease, and TSF

 OS overall survival, HR hazards ratio, CI confidence interval, CTI CRP-TyG index, CRP C-reactive protein, TyG triglyceride-glucose index, BMI body mass index, KPS karnofsky performance status, EORTC QLQ-C30 The European Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire-Core 30 (QLQ-C30), ECOG PS eastern cooperative oncology group performance status, PGSGA Patient Generated Subjective Global Assessment, TSF triceps skinfold thickness